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Aspirin (acetylsalicylic acid, ASA) is one of the oldest and
most commonly used drugs in the world. In the 5th century
BC, Hippocrates already prescribed leaves and bark of the
willow tree, consisting of ASA precursor salicin, to patients
with high fever and extreme pains. Nowadays, chronic low-
dose ASA is widely prescribed as a platelet aggregation
inhibitor in patients at risk for myocardial infarction or stroke.
In the Netherlands, it is the second most used drug with 7.6
million prescriptions in 2012 [1]. One of the main disadvan-
tages of ASA, however, is up-regulation of COX-2 in the
stomach, which may result in gastrointestinal side effects
including dyspepsia, gastrointestinal ulcers, and bleeding
[2]. These side effects instigated the development of alterna-
tives such as effervescent carbasalate calcium (ECC). ECC is
a salt formulation of ASA, which makes it more soluble and
theoretically prevents contact of high drug concentrations with
the gastric mucosa. Initial animal and clinical studies in vol-
unteers with high-dose drug administration indeed showed a
reduced incidence of gastrointestinal side effects in ECC users
[3, 4]. Later, however, patient studies with low-dose drugs
showed that the risk of ulcer development and bleeding is
similar for ECC and ASA [5, 6].
In the current issue of the Netherlands Heart Journal,
Focks et al. [7] describe that in addition to ulcer devel-
opment and bleeding, the risk of self-reported gastrointes-
tinal symptoms of ECC and ASA is also comparable. In
their observational study using questionnaires, gastroin-
testinal symptoms were similar in patients receiving ECC
and ASA. As the authors acknowledge in the discussion,
the study design involves the risk of response bias and
confounding by indication. Although the authors
corrected for potential confounders, it might still be pos-
sible that response bias and confounding mask a small
advantage of ECC. In combination with previous studies
comparing ECC and ASA on ulcer development, howev-
er, this study supports the hypothesis that gastrointestinal
side effects of ASA are mainly attributed to the systemic
presence of ASA rather than the local effect on the gastric
mucosa [5].
This article is a fine example of a phase 5 study; a relatively
new term referring to studies that investigate effectiveness and
side effects in a community after a therapy has proven to work
in large clinical trials [8, 9]. Conditions such as comorbidities,
decision-making of the practitioner, and patient compliance,
which are excluded or minimised in the previous phases but
play an important role in daily practice, are taken into account.
The first four study phases investigate whether a new therapy
works in defined –and often highly selected patient groups;
phase 5 analyses whether a community benefits from the new
therapy in daily practice. Although phase 5 studies are essen-
tial, they are infrequently conducted. Companies invest a lot
of money in new therapies and do not want to risk negative
consequences once a therapy is on the market. Researchers
may be less interested because the appreciation of phase 5
studies is generally lower due to the observational study
design and its inherent risk of bias, which will likely be
emphasised by colleagues and the company selling the
therapy.
The impact of this kind of research is nonetheless large. As
Focks et al. point out, ECC costs twice as much as ASA. In the
Netherlands, this results in 5 million euros annually (on top of
ASA costs) for a therapy, which in multiple studies shows no
additional beneficial effects. Focks and colleagues nicely
demonstrated that although ECC works better in theory, in
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pre-clinical studies, and even in some clinical studies, in daily
practice it is not superior to the cheaper ASA. In an era with
loads of new, expensive therapies and more cost-awareness,
community-based effectiveness studies are vital to gain max-
imum profit out of the available healthcare budget.
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